Close this search box.

Merck Unveils AIDDISON™: A Revolutionary AI-Driven Drug Discovery Platform

Merck's AIDDISON™ revolutionizes drug discovery, merging AI and machine learning to streamline synthesis and elevate new therapy success rates.

In a groundbreaking move, Merck, a global leader in science and technology, announced the launch of AIDDISON™, the first-ever software-as-a-service platform designed to revolutionize the pharmaceutical industry by integrating drug discovery and synthesis. This innovative solution marks a significant leap in the field of drug development, promising to enhance the efficiency and success rates of new drugs and therapies.

AIDDISON™ stands out as a unique convergence of generative AI, machine learning, and computer-aided drug design. This powerful combination allows for the virtual screening of compounds from an expansive universe of over 60 billion chemical targets. The software evaluates potential synthesis routes, aiming for safer, cost-effective, and higher-yield drug manufacturing. It further assists by recommending optimal chemicals, reagents, and building blocks for synthesis.

The software’s launch is a response to the pressing need for more efficient drug development processes. “With millions waiting for new medicines, the traditional drug development process, taking over 10 years and costing upwards of 1.9 billion Euros, is no longer sustainable,” stated Karen Madden, Chief Technology Officer, Life Science business sector of Merck. “AIDDISON™ harnesses generative AI to identify promising drug candidates in a vast chemical space and suggests the best synthesis routes, streamlining the development of target molecules in a sustainable manner.”

AIDDISON™ is a product of Merck’s commitment to redefining drug discovery. Trained on two decades of pharmaceutical R&D data, the software can identify compounds with essential drug properties like non-toxicity, solubility, and stability. This capability significantly increases the chances of success in the arduous journey of bringing new therapies to market—a journey where currently only about 10% of Phase I drug candidates reach patients.

The platform’s introduction is timely, considering AI’s potential in the pharmaceutical industry. AI and machine learning models like AIDDISON™ can unearth insights from vast datasets, improving the success rate of new therapies. By 2028, AI is projected to offer more than $70 billion in savings for the drug discovery process, potentially reducing time and costs by up to 70% for pharmaceutical companies.

Merck’s AIDDISON™ is not just a technological innovation; it represents the company’s ongoing dedication to scientific exploration and responsible entrepreneurship. With a history dating back to 1668, Merck continues to blend its rich heritage with cutting-edge technology, aiming to bring better therapies to patients faster. As a company with a presence in 66 countries and sales of € 22.2 billion in 2022, Merck leverages its strengths in life science, healthcare, and electronics to make a tangible difference in people’s lives.

Picture of AIM Research
AIM Research
AIM Research is the world's leading media and analyst firm dedicated to advancements and innovations in Artificial Intelligence. Reach out to us at
Subscribe to our Latest Insights
By clicking the “Continue” button, you are agreeing to the AIM Media Terms of Use and Privacy Policy.
Recognitions & Lists
Discover, Apply, and Contribute on Noteworthy Awards and Surveys from AIM
AIM Leaders Council
An invitation-only forum of senior executives in the Data Science and AI industry.
Stay Current with our In-Depth Insights
The Biggest Exclusive Gathering Of CDOs & Analytics Leaders In United States

MachineCon 2024
26 July 2024, New York

MachineCon 2024
Meet 100 Most Influential AI Leaders in USA
Our Latest Reports on AI Industry
Supercharge your top goals and objectives to reach new heights of success!

Cutting Edge Analysis and Trends for USA's AI Industry

Subscribe to our Newsletter